Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Disease 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

Dexamethasone 2 vistusertib 1 ricolinostat 1 pomalidomide 1 irinotecan sucrosofate 1 idelalisib 1 daratumumab 1 bermekimab 1 atezolizumab 1 alovudine 1 TKM-080301 1 TIC10 compound 1 S-Adenosylmethionine 1 Prostatectomy 1 Pluvicto 1 MicroRNAs 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Ipilimumab 1 Ga(III)-DOTATOC 1 Fluorouracil 1 Cyclophosphamide 1 Blood Specimen Collection 1 (225)Ac-PSMA-617 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Disease × vistusertib × Clear all

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed

Disease, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡